We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Amarin Corp PLC | NASDAQ:AMRN | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.008 | -0.87% | 0.91 | 0.90 | 0.92 | 0.934 | 0.8911 | 0.8946 | 462,783 | 21:13:37 |
NEW YORK, Sept. 9, 2014 /PRNewswire/ -- Wolf Popper LLP, lead counsel in the In re Amarin Corp. plc Securities Litigation, pending in the U.S. District Court for the District of New Jersey (Civil Action No. 13-cv-06663), is scheduled to file an amended complaint in the class action on September 19, 2014. That complaint will assert claims against Amarin and individual defendants arising out of the federal securities laws. The allegations in the action relate to defendants' alleged misrepresentations with respect to prospects for FDA approval of Amarin's Vascepa drug for the ANCHOR indication.
On July 8, 2013, Amarin filed a Prospectus Supplement for the issuance of 21.7 million American Depositary Shares (ADSs) through underwriters Citigroup Global Markets Inc. and Jefferies LLC. Investors who purchased Amarin ADSs on the secondary offering through the underwriters on or after July 9, 2013, are specifically urged to contact Wolf Popper LLP to discuss their legal rights to pursue claims in the amended complaint.
For more information, please contact:
Robert C. Finkel, Esq.
Tel.: 212.759.4600 or 877.370.7703 (toll free)
Fax: 212.486.2093 or 877.370.7704 (toll free)
Email: irrep@wolfpopper.com
website: www.wolfpopper.com
Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.
SOURCE Wolf Popper LLP
Copyright 2014 PR Newswire
1 Year Amarin Chart |
1 Month Amarin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions